Press releases
STORM’s lead programme is the first RNA methyltransferase inhibitor to enter clinical development.
Read more
Pre-clinical data strongly supports progression of a METTL3 inhibitor in an immuno-oncology setting. STC-15 is the first molecule specifically targeting METTL3 to enter clinical development.
Read more
Data demonstrates that STC-15, an oral METTL3 inhibitor, exhibits efficacy as a single agent and in combination with venetoclax using patient-derived tumor models. STC-15 Phase 1 study in solid tumors aims to identify doses and regimen for potential clinical studies in AML and solid tumors
Read more
Matthew Fyfe joins as Senior Vice President of Therapeutics. Beth Thomas promoted to Vice President of Medicinal Chemistry.
Read more
Proceeds will advance STORM’s potential first-in-class clinical program targeting METTL3 for treatment of solid tumors and leukemias. Financing will further expand STORM’s novel discovery platform to create additional products targeting RNA modification.
Read more